A Double-Blind Fixed-Dose Study of SM-13496 and Placebo in the Treatment of Schizophrenia.

Trial Profile

A Double-Blind Fixed-Dose Study of SM-13496 and Placebo in the Treatment of Schizophrenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Sumitomo Pharmaceuticals America
  • Most Recent Events

    • 20 Sep 2016 Results of pooled, post hoc analysis of this and other four trials presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 20 Sep 2016 Results of pooled, post hoc analysis of this trial and other 4 trials were presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 21 Oct 2014 Results of a post-hoc, pooled analysis of five 6-week, placebo-controlled, lurasidone trials were presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top